{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:52:19Z","timestamp":1787028739080,"version":"build-2736575974"},"reference-count":179,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Non-Hodgkin lymphomas (NHL) are a group of cancers that originate in the lymphatic system, especially from progenitor or mature B-cells, T-cells, or natural killer (NK) cells. NHL is the most common hematological malignancy worldwide and also the fourth most frequent type of cancer among pediatric patients. This cancer can occur in children of any age, but it is quite rare under the age of 5 years. In recent decades, available medicines and therapies have significantly improved the prognosis of patients with this cancer. However, some cases of NHL are treatment resistant. For this reason, immunotherapy, as a more targeted and personalized treatment strategy, is becoming increasingly important in the treatment of NHL in pediatric patients. The objective of the following review is to gather the latest available research results, conducted among pediatric and\/or adult patients with NHL, regarding one immunotherapy method, i.e., chimeric antigen receptor (CAR) T cell therapy. We focus on assessing the effectiveness of CAR-T cell therapy, which mainly targets B cell markers, CD19, CD20, and CD22, their connections with one another, sequential treatment, or connections with co-stimulatory molecules. In addition, we also evaluate the safety, aftermath (especially neurotoxicities) and limitations of CAR-T cell therapy.<\/jats:p>","DOI":"10.3390\/jpm13111595","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T05:04:56Z","timestamp":1699592696000},"page":"1595","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-9318","authenticated-orcid":false,"given":"Magdalena","family":"Ostojska","sequence":"first","affiliation":[{"name":"Student\u2019s Scientific Association of the Department of Pediatric Hematology, Oncology and Transplantation, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4012-2419","authenticated-orcid":false,"given":"Emilia","family":"Nowak","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association of the Department of Pediatric Hematology, Oncology and Transplantation, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8336-3029","authenticated-orcid":false,"given":"Julia","family":"Twardowska","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association of the Department of Pediatric Hematology, Oncology and Transplantation, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Lejman","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Faculty of Medicine, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7207-156X","authenticated-orcid":false,"given":"Joanna","family":"Zawitkowska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Transplantation, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.6004\/jnccn.2020.7608","article-title":"Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma","volume":"18","author":"Pommert","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_2","unstructured":"(2023, September 27). National Cancer Institute: NCCR*Explorer: An Interactive Website for NCCR Cancer Statistics. National Cancer Institute: Bethesda, MD, USA, Available online: https:\/\/nccrexplorer.ccdi.cancer.gov\/application.html?site=210&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on&hdn_view=1&advopt_display=1."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2008.07393.x","article-title":"Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: State of the science","volume":"144","author":"Hochberg","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_4","unstructured":"Graham, B.S., and Lynch, D.T. (2023, September 27). Burkitt Lymphoma. [Updated 2023 Aug 7], StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538148\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canep.2014.12.001","article-title":"Racial differences in three major NHL subtypes: Descriptive epidemiology","volume":"39","author":"Li","year":"2015","journal-title":"Cancer Epidemiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM199605093341906","article-title":"Non-Hodgkin\u2019s lymphoma in childhood","volume":"334","author":"Sandlund","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1182\/blood-2007-08-106021","article-title":"Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study","volume":"111","author":"Bluhm","year":"2008","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/1476-4598-9-305","article-title":"Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation","volume":"9","author":"Gravina","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/bjh.14009","article-title":"Paediatric non-Hodgkin lymphoma\u2014Perspectives in translational biology","volume":"173","author":"Shiramizu","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological malignancies: Advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","article-title":"Designing chimeric antigen receptors to effectively and safely target tumors","volume":"33","author":"Jensen","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1074-7613(00)80315-5","article-title":"Complex complexes: Signaling at the TCR","volume":"5","author":"Wange","year":"1996","journal-title":"Immunity"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1158\/0008-5472.CAN-10-0735","article-title":"Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts","volume":"70","author":"Kerkar","year":"2010","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: Chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/PPO.0000000000000031","article-title":"CD19-CAR trials","volume":"20","author":"Ramos","year":"2014","journal-title":"Cancer J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hon.3013","article-title":"Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper","volume":"40","author":"Bailly","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Yin, Z., Zhang, Y., and Wang, X. (2021). Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Biomark. Res., 9.","DOI":"10.1186\/s40364-021-00309-5"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101442","DOI":"10.1016\/j.beha.2023.101442","article-title":"Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma","volume":"36","author":"Chu","year":"2023","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1080\/10428194.2022.2076853","article-title":"Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: A single center experience","volume":"63","author":"Seitter","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12185-022-03481-y","article-title":"Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: Results from the phase 2 ELARA trial","volume":"117","author":"Fukuhara","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e22504","DOI":"10.1200\/JCO.2020.38.15_suppl.e22504","article-title":"Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric\/young adult (YA) patients (Pts) with relapsed\/refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL)","volume":"38","author":"Minard","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_34","first-page":"CD013365","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma","volume":"9","author":"Ernst","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_36","unstructured":"(2023, September 27). Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants with Relapsed\/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02625480?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=44&fbclid=IwAR2Dy_ZCZZstFLjYh7yYvWgzm-gcUeYo3iCj-fXYcWegWR3DmKRqGSjmpgI."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","article-title":"Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma","volume":"5","author":"Patrick","year":"2021","journal-title":"Blood Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): An open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"963689721996649","DOI":"10.1177\/0963689721996649","article-title":"Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"30","author":"Wang","year":"2021","journal-title":"Cell Transplant."},{"key":"ref_43","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"681984","DOI":"10.3389\/fimmu.2021.681984","article-title":"A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions","volume":"12","author":"Marofi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1126\/science.abb8008","article-title":"Binding mechanisms of therapeutic antibodies to human CD20","volume":"369","author":"Kumar","year":"2020","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/14712598.2020.1822318","article-title":"Anti-CD20 treatment for B-cell malignancies: Current status and future directions","volume":"21","author":"Klein","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jcyt.2022.05.001","article-title":"CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory\/relapsed B-cell non-Hodgkin lymphoma","volume":"24","author":"Cheng","year":"2022","journal-title":"Cytotherapy"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells Expressing CD19\/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3389\/fimmu.2018.02235","article-title":"CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity","volume":"9","author":"Clark","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Huang, L., Li, J., Yang, J., Zhang, X., Zhang, M., He, J., Zhang, G., Li, W., Wang, H., and Li, J. (2022). Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory\/Relapsed B-Cell Lymphoma. Cells, 11.","DOI":"10.3390\/cells11244085"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: Phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"969660","DOI":"10.3389\/fimmu.2022.969660","article-title":"Decitabine-primed tandem CD19\/CD22 CAR-T therapy in relapsed\/refractory diffuse large B-cell lymphoma patients","volume":"13","author":"Qu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: A phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"910.e1","DOI":"10.1016\/j.jtct.2021.08.012","article-title":"CD19\/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed\/Refractory Aggressive B Cell Lymphomas","volume":"27","author":"Cao","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"879983","DOI":"10.3389\/fimmu.2022.879983","article-title":"Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s00262-021-02850-6","article-title":"CAR19\/22 T cell therapy in adult refractory Burkitt\u2019s lymphoma","volume":"70","author":"Zhou","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jcyt.2020.01.008","article-title":"Efficacy and toxicity for CD22\/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed\/refractory aggressive B-cell lymphoma involving the gastrointestinal tract","volume":"22","author":"Zeng","year":"2020","journal-title":"Cytotherapy"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.2019002008","article-title":"Early response observed in pediatric patients with relapsed\/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells","volume":"135","author":"Zhang","year":"2020","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","article-title":"Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma","volume":"6","author":"Liu","year":"2022","journal-title":"Blood Adv."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00432-020-03198-7","article-title":"Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: A case report and literature review","volume":"146","author":"Du","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1182\/blood-2019-125753","article-title":"Early Response Observed in Pediatric Patients with Refractory\/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"640166","DOI":"10.3389\/fonc.2021.640166","article-title":"Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL","volume":"11","author":"Meng","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_66","unstructured":"(2023, September 27). A Study of CAR-T Cells Therapy for Patients with Relapsed and\/or Refractory Central Nervous System Hematological Malignancies, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04532203?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&rank=10."},{"key":"ref_67","unstructured":"(2023, September 27). Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN), Available online: https:\/\/clinicaltrials.gov\/study\/NCT01853631?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=2&rank=11."},{"key":"ref_68","unstructured":"(2023, September 27). A Study of Murine CD19 CAR-T Therapy for Patients with Relapsed or Refractory CD19+ B-Cell Hematological Malignancies, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04532281?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=2&rank=12."},{"key":"ref_69","unstructured":"(2023, September 27). A Study of Humanized CD19 CAR-T Cells Therapy for Patients with Relapsed and\/or Refractory B-Cell ALL and B-Cell NHL, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04532268?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=2&rank=13."},{"key":"ref_70","unstructured":"(2023, September 27). CD19+Targeted CAR-T Cell Therapy for Relapsed\/Refractory CD19+ B Cell Leukemia and Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04271410?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=2&rank=14."},{"key":"ref_71","unstructured":"(2023, September 27). Immunotherapy for High Risk\/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-Cell Non-Hodgkin\u2019s Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)\/Small Lymphocytic Lymphoma (SLL) Using CAR T-Cells to Target CD19 (ALLCAR19), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02935257?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=2&rank=15."},{"key":"ref_72","unstructured":"(2023, September 27). CD19 CAR T-Cell Therapy for R\/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06027957?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=2&rank=19."},{"key":"ref_73","unstructured":"(2023, September 27). Anti-CD19, Dual Co-stimulatory (4-1BB, CD3\u03b6) Chimeric Antigen Receptor T-Cells in Patients with Relapsed\/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001\/EXC002), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03938987?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=3&rank=26."},{"key":"ref_74","unstructured":"(2023, September 27). Phase 1\/2 Study of CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR-T) for Relapsed or Refractory B-Cell Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05326243?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=3&rank=28."},{"key":"ref_75","unstructured":"(2023, September 27). Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed\/Refractory B-Cell Lymphoma (CAR-T), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05143112?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=34."},{"key":"ref_76","unstructured":"(2023, September 27). ENABLE (Engaging Toll-like Receptor Signalling for B-Cell Lymphoma Chimeric Antigen Receptor Therapy) (ENABLE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04049513?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=35&tab=table."},{"key":"ref_77","unstructured":"(2023, September 27). CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed\/Refractory CD19+ ALL and DLBCL or PML, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04787263?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=36."},{"key":"ref_78","unstructured":"(2023, September 27). UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04544592?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=38."},{"key":"ref_79","unstructured":"(2023, September 27). A Study of CT-RD06 Cell Injection in Patients with Relapsed or Refractory CD19+ B-Cell Hematological Malignancy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04226989?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=41."},{"key":"ref_80","unstructured":"(2023, September 27). MB-CART19.1 r\/r CD19+ B-Cell Malignancies (BCM), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03853616?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=42."},{"key":"ref_81","unstructured":"(2023, September 27). A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects with Relapsed\/Refractory (r\/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03743246?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=45."},{"key":"ref_82","unstructured":"(2023, September 27). Chidamide Bridging for CAR-T Therapy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05370547?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&rank=5."},{"key":"ref_83","unstructured":"(2023, September 27). Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) (CARPASCIO), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02050347?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=3&rank=24."},{"key":"ref_84","unstructured":"(2023, September 27). CD19.CAR Allogeneic NKT for Patients with Relapsed or Refractory B-Cell Malignancies (ANCHOR), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03774654?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=3&rank=25."},{"key":"ref_85","unstructured":"(2023, September 27). Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (ANCHOR2), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05487651?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=33."},{"key":"ref_86","unstructured":"(2023, September 27). Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\/R B-NHL Patients, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05098613?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&rank=2."},{"key":"ref_87","unstructured":"(2023, September 27). Clinical Study of SL19 + 22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05206071?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&rank=3."},{"key":"ref_88","unstructured":"(2023, September 27). Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients with Relapsed or Refractory B Cell Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04715217?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=2&rank=17."},{"key":"ref_89","unstructured":"(2023, September 27). A Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed\/Refractory B Cell Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04782193?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=2&rank=18."},{"key":"ref_90","unstructured":"(2023, September 27). Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed\/Refractory B Cell Leukemia and Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04648475?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=3&rank=22."},{"key":"ref_91","unstructured":"(2023, September 27). CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed\/Refractory B Cell Leukemia and Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04649983?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=3&rank=23."},{"key":"ref_92","unstructured":"(2023, September 27). CD19\/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19\/CD22-Expressing B Cell Malignancies, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03448393?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=3&rank=29."},{"key":"ref_93","unstructured":"(2023, September 27). A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed\/Refractory Non Hodgkin\u2019s Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04666168?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&rank=4."},{"key":"ref_94","unstructured":"(2023, September 27). Multi-CAR-T Cells Targeting B Cell Lymphomas, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04429438?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=37."},{"key":"ref_95","unstructured":"(2023, September 27). CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (RELY-30), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02917083?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&rank=1."},{"key":"ref_96","unstructured":"(2023, September 27). CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03383965?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=2&rank=20."},{"key":"ref_97","unstructured":"(2023, September 27). CD30-Directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas (CART30), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02259556?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=31."},{"key":"ref_98","unstructured":"(2023, September 27). Study of CD30 CAR for Relapsed\/Refractory CD30+ HL and CD30+ NHL, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02690545?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=40."},{"key":"ref_99","unstructured":"Allogeneic CD30 (2023, September 27). CAR-EBVSTs in Patients with Relapsed or Refractory CD30-Positive Lymphomas, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04288726?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=3&rank=21."},{"key":"ref_100","unstructured":"(2023, September 27). Anti-CD5 CAR T Cells for Relapsed\/Refractory T Cell Malignancies (CD5CAR-T), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04594135?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&rank=6."},{"key":"ref_101","unstructured":"(2023, September 27). Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03081910?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=3&rank=30."},{"key":"ref_102","unstructured":"(2023, September 27). Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05290155?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=2&rank=16."},{"key":"ref_103","unstructured":"(2023, September 27). Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed on Autologous T Cells, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03690011?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&page=3&rank=27."},{"key":"ref_104","unstructured":"(2023, September 27). Safety and Efficacy of ThisCART7 in Patients with Refractory or Relapsed T Cell Malignancies, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05127135?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=32."},{"key":"ref_105","unstructured":"(2023, September 27). Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04823091?cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&distance=50&aggFilters=ages:child,status:rec&page=4&rank=39."},{"key":"ref_106","unstructured":"(2023, September 27). CD 70 CAR T for Patients with CD70 Positive Malignant Hematologic Diseases, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04662294?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&rank=7."},{"key":"ref_107","unstructured":"(2023, September 27). CAR-T Cells in the Treatment of Malignant Hematological Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05619861?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&rank=8."},{"key":"ref_108","unstructured":"(2023, September 27). Clinical Study on CAR-T Targeting Ig\u03b2 Targets in Refractory Relapsed Non-Hodgkin\u2019s Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05312476?distance=50&cond=Non-Hodgkin%20Lymphoma&intr=CAR-T&aggFilters=ages:child,status:rec&fbclid=IwAR2N4dmBF0CHpOhuE23F_Q_XnpqkD2rVukfgKVhRBeqdxnrH4PN7EITI_hE&rank=9."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.retram.2018.03.003","article-title":"Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy","volume":"66","author":"Gauthier","year":"2018","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","article-title":"Understanding the immunodeficiency in chronic lymphocytic leukemia: Potential clinical implications","volume":"27","author":"Riches","year":"2013","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4037\/aacnacc2022936","article-title":"Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations","volume":"33","author":"Owusu","year":"2022","journal-title":"AACN Adv. Crit. Care"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e005898","DOI":"10.1136\/jitc-2022-005898","article-title":"CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity","volume":"11","author":"Jess","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/s13238-017-0400-z","article-title":"Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment","volume":"8","author":"Wang","year":"2017","journal-title":"Protein Cell"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/CCM.0b013e3182a66b76","article-title":"Cornell Assessment of Pediatric Delirium: A valid, rapid, observational tool for screening delirium in the PICU*","volume":"42","author":"Traube","year":"2014","journal-title":"Crit. Care Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bjh.16951","article-title":"Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy","volume":"191","author":"Liu","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_130","unstructured":"(2023, September 27). Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: A position paper","volume":"49","author":"Iacoboni","year":"2021","journal-title":"Infection"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1182\/blood.2019000936","article-title":"Pediatric hemophagocytic lymphohistiocytosis","volume":"135","author":"Canna","year":"2020","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Sharma, N., Reagan, P.M., and Liesveld, J.L. (2022). Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem. Cancers, 14.","DOI":"10.3390\/cancers14061501"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s40778-018-0139-3","article-title":"The Role of Interferon-Gamma in Hematopoietic Stem Cell Development, Homeostasis, and Disease","volume":"4","author":"King","year":"2018","journal-title":"Curr. Stem. Cell Rep."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Chabannon","year":"2020","journal-title":"Haematologica"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"92","DOI":"10.15264\/cpho.2022.29.2.92","article-title":"Anakinra to Mitigate Hemophagocytic Lymphohistiocytosis-Like Toxicity Following Chimeric Antigen Receptor T-cell Therapy in Pediatric B-cell ALL","volume":"29","author":"Lee","year":"2022","journal-title":"Clin. Pediatr. Hematol. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","article-title":"A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis","volume":"97","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.12542","article-title":"Rasburicase in the prevention of laboratory\/clinical tumour lysis syndrome in children with advanced mature B-NHL: A Children\u2019s Oncology Group Report","volume":"163","author":"Galardy","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"663201","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions Related to CAR-T Cell Therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1080\/10428194.2020.1786563","article-title":"Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas","volume":"61","author":"Johnson","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: Patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_152","unstructured":"(2023, September 27). FDA Approves CAR-T Cell Therapy to Treat Adults with Certain Types of Large B-Cell Lymphoma, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-car-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR T cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_154","first-page":"SP35","article-title":"with Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage","volume":"24","author":"Caffrey","year":"2018","journal-title":"Am. J. Manag. Care"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1158\/1538-7445.AM2018-1631","article-title":"T cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential","volume":"78","author":"Das","year":"2018","journal-title":"Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment","volume":"10","author":"Mutis","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: How cancer cells resist CAR T cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/nm1676","article-title":"T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection","volume":"13","author":"Stephan","year":"2007","journal-title":"Nat. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CM9.0000000000001294","article-title":"R-CHOP resistance in diffuse large B-cell lymphoma: Biological and molecular mechanisms","volume":"134","author":"Wang","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2326-6066.CIR-18-0439","article-title":"Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL","volume":"7","author":"Xiao","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","article-title":"Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"25","author":"Yan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3389\/fonc.2020.01243","article-title":"CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions","volume":"10","author":"Ganzetti","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","article-title":"Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel","volume":"26","author":"Faramand","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1038\/s41467-022-32960-3","article-title":"CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies","volume":"13","author":"Hu","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1067\/mai.2002.124894","article-title":"Intestinal Bifidobacterium species induce varying cytokine production","volume":"109","author":"He","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.cell.2016.11.046","article-title":"Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity","volume":"167","author":"Schirmer","year":"2016","journal-title":"Cell"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-065X.2010.00915.x","article-title":"Control of immune response by amino acid metabolism","volume":"236","author":"Grohmann","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1182\/bloodadvances.2022007676","article-title":"The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes","volume":"6","author":"Faruqi","year":"2022","journal-title":"Blood Adv."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"101445","DOI":"10.1016\/j.beha.2023.101445","article-title":"Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults","volume":"36","author":"Belsky","year":"2023","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/11\/1595\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:21:01Z","timestamp":1760131261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/11\/1595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":179,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jpm13111595"],"URL":"https:\/\/doi.org\/10.3390\/jpm13111595","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]}}}